Aspergillosis pathogenesis, clinical manifestations, and therapy

Infectious Disease Clinics of North America

Volumn 16, Issue 4, 2002, Pages 875-894

  Marr, Kieren A ^a   Patterson, Thomas ^b   Denning, David ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Mail Code 7881 ^*  (United States)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ITRACONAZOLE; VORICONAZOLE;

ALLERGIC DISEASE; ASPERGILLOSIS; ASPERGILLUS; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; LUNG ASPERGILLOSIS; NEPHROTOXICITY; PATHOGENESIS; REVIEW; RISK FACTOR; SINUSITIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS; ASPERGILLUS FUMIGATUS; DISEASE MANAGEMENT; HUMANS; IMMUNOCOMPROMISED HOST; LUNG DISEASES, FUNGAL;

EID: 0036904836     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(02)00035-1     Document Type: Review

References (125)

1. Kwon-Chung KJ, Bennett JE. Medical Mycology. Philadelphia: Lea & Febiger; 1992, p. 81-104.
2. deRepentigny L, Petitbois S, Boushira M, et al. Acquired immunity in experimental murine aspergillosis is mediated by macrophages. Infect Immunol 1993;61:3791-802.
3. Duong M, Ouellet N, Simard M, et al. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect Dis 1998;178:1472-82.
4. Schaffner A. Macrophage-Aspergillus interactions. Immunology 1994;60:545-52.
5. Schaffner A, Douglas H, Braude AI, et al. Killing of Aspergillus spores depends on the anatomical source of the macrophage. Infect Immunol 1983;42:1109-15.
6. Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984;150:752-60.
7. Allen M, Harbeck R, Smith B, et al. Binding of rat and human surfactant proteins A and D to Aspergillus fumigatus conidia. Infect Immunol 1999;67:4563-9.
8. Crosdale DJ, Poulton KV, Ollier WE, et al. Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J Infect Dis 2001;184:653-6.
9. Roilides E, Blake C, Holmes A, et al. Granulocyte-macrophage colony-stimulating factor and interferon-γ prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996;34:63-9.
10. Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. J Clin Invest 1982;69:617-31.
11. Cenci E, Mencacci A, Bacci A, et al. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000;165:381-8.
12. Cenci E, Mencacci A, Fe d'Ostiani C, et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998;178:1750-60.
13. Cenci E, Perito S, Enssle K, et al. Thl and Th2 cytokines in mice with invasive aspergillosis. Infect Immunol 1997;65:564-70.
14. + Th2-like T cell lines in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1994;94:215-21.
15. Berenguer J, Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis: Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med 1995;152:1079-86.
16. Sturtevant J, Latge JP. Participation of complement in the phagocytosis of the conidia of Aspergillus fumigatus by human polymorphonuclear cells. J Infect Dis 1992;166:580-6.
17. Tronchin G, Bouchara JP, Ferron M, et al. Cell surface properties of Aspergillus fumigatus conidia: Correlation between adherence, agglutination, and rearrangements of the cell wall. Can J Microbiol 1995;41:714-21.
18. Tronchin G, Esnault K, Renier G, et al. Expression and identification of a laminin-binding protein in Aspergillus fumigatus conidia. Infect Immunol 1997;65:9-15.
19. Thau N, Monod M, Crestani B, et al. Rodletless mutants of Aspergillus fumigatus. Infect Immunol 1994;62:4380-8.
20. Jahn B, Boukhallouk F, Lotz J, et al. Interaction of human phagocytes with pigmentless Aspergillus conidia. Infect Immunol 2000;68:3736-9.
21. Tsai HF, Chang YC, Washburn RG, et al. The developmentally regulated alb1 gene of Aspergillus fumigatus: Its role in modulation of conidial morphology and virulence. J Bacteriol 1998;180:3031-8.
22. Calera JA, Paris S, Monod M, et al. Cloning and disruption of the antigenic catalase gene of Aspergillus fumigatus. Infect Immunol 1997;65:4718-24.
23. Takasuka T, Sayers NM, Anderson MJ, et al. Asgergillus fumigatus catalases: Cloning of an Aspergillus nidulans catalase B homologue and evidence for at least three catalases. FEMS Immunol Med Microbiol 1999;23:125-33.
24. Holdom M, Hay R, Hamilton A. Purification, N-terminal amino acid sequence and partial characterization of a Cu,Zn superoxide dismutase from the pathogenic fungus, Aspergillus fumigatus. Free Radic Res 1996;22:519-31.
25. Birch M, Robson G, Law D, et al. Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect Immunol 1996;64:751-5.
26. Monod M, Paris S, Sanglard D, et al. Isolation and characterization of a secreted metalloprotease of Aspergillus fumigatus. Infect Immunol 1993;61:4099-104.
27. Monod M, Paris S, Sarfati J, et al. Virulence of alkaline protease-deficient mutants of Aspergillus fumigatus. FEMS Microbiol Lett 1993;80:39-46.
28. Monod M, Togni G, Rahalison L, et al. Isolation and characterisation of an extracellular alkaline protease of Aspergillus fumigatus. J Med Microbiol 1991;35:23-8.
29. Tang C, Cohen J, Krausz T, et al. The alkaline protease of Aspergillus fumigatus is not a virulence determinant in two murine models of the invasive pulmonary aspergillosis. Infect Immunol 1993;61:1650-6.
30. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999;12:310-50.
31. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17.
32. Moore CB, Sayers N, Mosquera J, et al. Antifungal drug resistance in Aspergillus. J Infect 2000;41:203-20.
33. Sutton DA, Sanche SE, Revankar SG, et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999;37:2343-5.
34. Tritz D, Woods G. Fatal disseminated infection with Aspergillus terreus in the immunocompromised patient. Clin Infect Dis 1993;16:118-22.
35. Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998;77:345-54.
36. Wald A, Leisenring W, van Burik J, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-66.
37. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic Aspergillus species recovered from a hospital water system. Presented at the International Conference of Antimicrobial Agents and Chemotherapy. San Francisco, CA, 1999.
38. Warris A, Voss A, Abrahamsen TG, Verweij PE. Contamination of Hospital Water With Aspergillus Fumigatus and Other Molds.
39. Lass-Florl C, Rath P, Niederwieser D, et al. Aspergillus terreus infections in haematological malignancies: Molecular epidemiology suggests association with in-hospital plants. J Hosp Infect 2000;46:31-5.
40. el-Dahr JM, Fink R, Selden R, et al. Development of immune responses to Aspergillus at an early age in children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150(6 pt 1):1513-8.
41. Kumar R, Gaur SN. Prevalence of allergic bronchopulmonary aspergillosis in patients with bronchial asthma. Asian Pac J Allergy Immunol 2000;18:181-5.
42. Eaton T, Garrett J, Milne D, et al. Allergic bronchopulmonary aspergillosis in the asthma clinic: A prospective evaluation of CT in the diagnostic algorithm. Chest 2000;118:66-72.
43. Rosenberg M, Patterson R, Mintzer R, et al. Clinical and immunonological criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977;86:405-14.
44. Elphick H, Southern K. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 4, 2000;4:CD002204.
45. Schwartz H, Greenberger P. The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serological and radiological criteria in patients at risk. J Lab Clin Med 1991;117:138-42.
46. Chauhan B, Knutsen A, Hutcheson P, et al. T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis. J Clin Invest 1996;97:2324-31.
47. Kurup VP, Banerjee B. Fungal allergens and peptide epitopes. Peptides 2000;21:589-99.
48. Kurup VP, Hari V, Guo J, et al. Aspergillus fumigatus peptides differentially express Th1 and Th2 cytokines. Peptides 1996;17:183-90.
49. Chauhan B, Santiago L, Hutcheson PS, et al. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2000;106:723-9.
50. Chauhan B, Santiago L, Kirschmann DA, et al. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. J Immunol 1997;159:4072-6.
51. Horner WE, Helbling A, Salvaggio JE, et al. Fungal allergens. Clin Microbiol Rev 1995;8:161-79.
52. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000;342:756-62.
53. Israel H, Lenchner G, Atkinson G. Sarcoidosis and aspergilloma. Chest 1982;82:430-2.
54. Kawamura S, Maesaki S, Tomono K, et al. Clinical evaluation of 61 patients with pulmonary aspergilloma. Intern Med 2000;39:209-12.
55. Kirsten D, Rieger U, Amthor M, et al. Invasive aspergillosis in cavitary lung sarcoidosis. Pneumologie 1992;46:239-42.
56. Staples CA, Kang EY, Wright JL, et al. Invasive pulmonary aspergillosis in AIDS: Radiographic, CT, and pathologic findings. Radiology 1995;196:409-14.
57. Wollschlager C, Kan F. Aspergilloma complicating sarcoidosis: A prospective study of 100 patients. Chest 1984;86:585-8.
58. Shah A, Khan ZU, Chaturvedi S, et al. Allergic bronchopulmonary aspergillosis with coexistent aspergilloma: A long-term followup. J Asthma 1989;26:109-15.
59. Chen J, Chang Y, Luh S, et al. Surgical treatment for pulmonary aspergilloma: A 28 year experience. Thorax 1997;52:810-3.
60. Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001;7(suppl 2):25-31.
61. Gefter WB. The spectrum of pulmonary aspergillosis. J Thorac Imaging 1992;7:56-74.
62. Kim Y, Lee KS, Jung KJ, et al. Halo sign on high resolution CT: Findings in spectrum of pulmonary diseases with pathologic correlation. J Comput Assist Tomogr 1999;23:622-6.
63. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000;30:696-709.
64. Kuhn F, Javer A. Allergic fungal sinusitis: A four-year follow-up. Am J Rhinol 2000;14:149-56.
65. Corey J, Delsupehe K, Ferguson B. Allergic fungal sinusitis: Allergic, infectious, or both? Otolaryngol Head Neck Surg 1995;113:110-9.
66. Washburn RG. Fungal sinusitis. Curr Clin Top Infect Dis 1998;18:60-74.
67. Nussenbaum B, Marple B, Schwade N. Characteristics of bony erosion in allergic fungal rhinosinusitis. Otolaryngol Head Neck Surg 2001;124:150-4.
68. Andes D, Proctor R, Bush R, et al. Report of successful prolonged antifungal therapy for refractory allergic fungal sinusitis. Clin Infect Dis 2000;31:202-4.
69. Marple B, Mabry R. Comprehensive management of allergic fungal sinusitis. Am J Rhinol 1998;12:263-8.
70. Stringer S, Ryan M. Chronic invasive fungal rhinosinusitis. Otolaryngol Clin North Am 2000;33:375-87.
71. Dhong H, Jung J, Park J. Diagnostic accuracy in sinus fungus balls: CT scan and operative findings. Am J Rhinol 2000;14:227-31.
72. Ferguson B. Fungus balls of the paranasal sinuses. Otolaryngol Clin North Am 2000; 33:389-98.
73. Sterman BM. Sinus surgery in bone marrow transplantation patients. Am J Rhinol 1999;13:315-7.
74. Talbot GH, Huang A, Provencher M. Invasive Aspergillus rhinosinusitis in patients with acute leukemia. Rev Infect Dis 1991;13:219-32.
75. Iwen P, Reed E, Armitage J, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol 1993;14:131-9.
76. Kavanagh KT, Hughes WT, Parham DM, et al. Fungal sinusitis in immunocompromised children with neoplasms. Ann Otol Rhinol Laryngol 1991;100(4 pt 1):331-6.
77. Alrajhi AA, Enani M, Mahasin Z, et al. Chronic invasive aspergillosis of the paranasal sinuses in immunocompetent hosts from Saudi Arabia. Am J Trop Med Hyg 2001;65:83-6.
78. Khoo SH, Denning DW. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1994;19(suppl 1):S41-8.
79. Hines DW, Haber MH, Yaremko L, et al. Pseudomembranous tracheobronchitis caused by Aspergillus. Am Rev Respir Dis 1991;143:1408-11.
80. Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:654-62.
81. Kemper CA, Hostetler JS, Follansbee SE, et al. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis 1993;17:344-52.
82. Kountakis SE, Kemper Jr. JV, Chang CY, et al. Osteomyelitis of the base of the skull secondary to Aspergillus. Am J Otolaryngol 1997;18:19-22.
83. Lortholary O, Meyohas MC, Dupont B, et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: Report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med 1993;95:177-87.
84. Barnes C, Berkowitz R, Curtis N, et al. Aspergillus laryngotracheobronchial infection in a 6-year-old girl following bone marrow transplantation. Int J Pediatr Otorhinolaryngol 2001;59:59-62.
85. Berlinger NT, Freeman TJ. Acute airway obstruction due to necrotizing tracheobronchial aspergillosis in immunocompromised patients: A new clinical entity. Ann Otol Rhinol Laryngol 1989;98:718-20.
86. Koh LP, Goh YT, Linn YC, et al. Pseudomembranous tracheobronchitis caused by Aspergillus in a patient after peripheral blood stem cell transplantation. Ann Acad Med Singapore 2000;29:531-3.
87. Cooper JA, Weinbaum DL, Aldrich TK, et al. Invasive aspergillosis of the lung and pericardium in a nonimmunocompromised 33 year old man. Am J Med 1981;71:903-7.
88. Karam GH, Griffin Jr. FM. Invasive pulmonary aspergillosis in nonimmunocompromised, nonneutropenic hosts. Rev Infect Dis 1986;8:357-63.
89. Ruhnke M, Eichenauer E, Searle J, et al. Fulminant tracheobronchial and pulmonary aspergillosis complicating imported Plasmodium falciparum malaria in an apparently immunocompetent woman. Clin Infect Dis 2000;30:938-40.
90. Sidorov J. Aspergillosis in a healthy host. South Med J 1988;81:679.
91. Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation: A new form of invasive aspergillosis. Am Rev Respir Dis 1991;144(3 pt 1):552-6.
92. Mehrad B, Paciocco G, Martinez F, et al. Spectrum of Aspergillus infections in lung transplant recipients: Case series and review of the literature. Chest 2001;119:169-75.
93. Hadjiliadis D, Howell DN, Davis RD, et al. Anastomotic infections in lung transplant recipients. Ann Transplant 2000;5:13-9.
94. Boettcher H, Bewig B, Hirt SW, et al. Topical amphotericin B application in severe bronchial aspergillosis after lung transplantation: Report of experiences in 3 cases. J Heart Lung Transplant 2000;19:1224-7.
95. Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997;29:627-8.
96. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
97. Baddley J, Stroud T, Salzman D, et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319-24.
98. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997;19:801-8.
99. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changing epidemiology and risk factors. Blood 2002 (in press).
100. Mori M, Galvin JR, Barloon TJ, et al. Fungal pulmonary infections after bone marrow transplantation: Evaluation with radiography and CT. Radiology 1991;178:721-6.
101. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001;19:253-9.
102. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996;100:171-8.
103. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 1999;37:3223-8.
104. Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood 2001;97: 1604-10.
105. Bretagne S, Costa J, Marmorat-Khoung A, et al. Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR. J Clin Microbiol 1995;33:1164-8.
106. Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997;35:1353-60.
107. Kawamura S, Maesaki S, Noda T, et al. Comparison between PCR and detection of antigen in sera for diagnosis of pulmonary aspergillosis. J Clin Microbiol 1999;37:218-20.
108. Duthie R, Denning D. Aspergillus fungemia: Report of two cases and review. Clin Infect Dis 1995;20:598-605.
109. Kontoyiannis DP, Sumoza D, Tarrand J, et al. Significance of aspergillemia in patients with cancer: A 10-year study. Clin Infect Dis 2000;31:188-9.
110. van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol 1998;36:3115-21.
111. Harousseau J, Dekker A, Stamatoullas-Bastard A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematologic malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000;44:1887-93.
112. Menichetti F, DelFavero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1999;28:250-5.
113. Morgenstern G, Prentice A, Prentice H, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with hematological malignancies. Br J Haematol 1999;105:901-11.
114. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
115. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
116. Walsh T, Finberg R, Arndt C, et al. Liposomal amphotericin B for empiric therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71.
117. Walsh T, Pappas P, Winston D, et al. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: A randomized, international, multicenter trial. New Engl J Med 2002;346:225-34.
118. Hebrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
119. Denning D, Lee J, Hostetler J, et al. Mycoses study group multicenter tiral of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-44.
120. Stevens D, Lee J. Analysis of compassionate use itraconazole for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997;157:1857-62.
121. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250-60.
122. Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001;32:358-66.
123. Ribaud P, Chastang C, Latge J, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999;28:322-30.
124. Yeghen T, Kibbler C, Prentice H, et al. Management of invasive pulmonary aspergillosis in hematology patients: A review of 87 consecutive cases at a single institution. Clin Infect Dis 2000;31:859-68.
125. Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998;26:1098-103.